Actos Linked to Bladder Cancer by Columbia University Expert
Scientific studies indicate Takeda Pharmaceutical Co. diabetes drug Actos (pioglitazone) contributed to the development of malignant bladder tumors, according to a Columbia University researcher who testified on behalf of a plaintiff who allegedly developed cancer after three years of taking the controversial diabetes medication.